Investeringsforeningen C Worldwide
19.12.2019 12:05:54 CET | Globenewswire | Press release
Nasdaq Copenhagen A/S 19. december 2019
Nikolaj Plads 6
1067 København K
Forventede udbytter for regnskabsåret 2019
Investeringsforeningen C WorldWide har medio december opgjort de forventede udbytter (angivet i kr. pr. andel), som fremgår nedenfor. Dette er foreløbige beløb, og disse kan således ændre sig, når årsrapporten foreligger. Nærmere information om den forventede udlodningsdato i januar 2020 følger senere. Foreningen forventer ca. medio januar at kunne offentliggøre de endelige udbyttesatser.
De foreventede udbytter er opgjort til:
Afdeling kr. pr. andel
DK0010157965 Globale Aktier KL A 61,70
DK0060287217 Globale Aktier Etik KL 29,20
DK0010312529 Stabile Aktier KL 7,00
DK0010249655 Danmark KL 21,30
DK0015945166 Emerging Markets KL 0,00
DK0060057644 Asien KL A 0,20
Med venlig hilsen
Investeringsforeningen C WorldWide
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
Henrik Brandt
Direktør
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
Orion Oyj18.9.2026 18:00:00 CEST | Press release
Orion Corporation: Acquisition of own shares during week 38, 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom